KRAS Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact) benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for 9 Targeted Therapies for Use in Patients with Advanced Non-Small Cell Lung Cancer PREMIA Holdings (HK) Ltd. Hong Kong, HONG KONG
TOKYO and XIAMEN, China, June 30, 2021 (GLOBE NEWSWIRE) Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the AmoyDx
® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”), an in vitro diagnostic reagent developed as a companion diagnostic for multiple anti-cancer agents, was approved by Ministry of Health, Labour and Welfare (MHLW) for production and marketing in Japan on June 25, 2021.
Share this article
Share this article
ResearchAndMarkets.com s offering.
The scope of the report includes liquid biopsy technologies, applications, industry subsegments, biomarker technologies, major funding initiatives, patents and companies. The market sizes for liquid biopsy diagnostics are given for 2019, 2020 and 2025 (forecasted).
Liquid biopsy is creating a paradigm shift in medicine, and this is opening significant market opportunities. These market segments are particularly promising for the following liquid biopsy applications: noninvasive prenatal screening for average-risk populations; cancer screening and early detection; and recurrence monitoring for cancer patients.
Biomarker types of most interest include cell-free DNA (cfDNA), circulating tumor cells (CTCs) and exosomes. Ongoing advances in sensitive molecular technologies such as next-generation DNA sequencing (NGS) and digital polymerase chain reaction (dPCR) enable the detection of biomarkers that are present
Share:
New York, April 09, 2021 (GLOBE NEWSWIRE) Reportlinker.com announces the release of the report BRAF Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact) - https://www.reportlinker.com/p05948850/?utm source=GNW
The model discusses in detail the impact of COVID-19 on BRAF Tests market for the year 2020 and beyond. Melanoma is accounted for as the nineteenth most basic malignant growth around the world, with assessed age-standardized frequency rates of 2.8-3.1 per 100,000 . There is significant variety in frequency between nations, with the most high rates seen in Australia (37 for every 100,000) and the least in South-Central Asia (0.2 per 100,000). This pattern is ascribed to varieties in racial skin phenotype, just as contrasts in sun exposure around the globe.The fundamental environmental factor causing cutaneous melanoma is UV radiation.
Share:
New York, April 09, 2021 (GLOBE NEWSWIRE) Reportlinker.com announces the release of the report ALK Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact) - https://www.reportlinker.com/p05948847/?utm source=GNW
The model discusses in detail the impact of COVID-19 on ALK Tests market for the year 2020 and beyond.Globally, lung cancer is the second most common cancer in men and the third most common cancer in women.
Secondary sources estimate that approximately 2.0 million new cases of lung cancer were reported worldwide in 2018. Cigarette smoking is the dominant risk factor associated with lung cancer across all age groups, with approximately 80% of male and 45% of female lung cancer cases worldwide attributed to smoking.